A Study of Selumetinib in Chinese Paediatric and Adult Subjects with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Trial Identifier:	D1346C00011
Sponsor:	AstraZeneca
Collaborator:	Merck Sharp & Dohme Corp.
Start Date:	December 2020
Primary Completion Date:	August 2022
Study Completion Date:	August 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	Chinese (Simplified) Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CN	shanghai, CN, 200011
CN	Shanghai, CN, CN-200092

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.